Close
Sukeshi Patel Arora, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Sukeshi Patel Arora, MD
Sukeshi Patel Arora, MD, is an associate professor in the Division of Hematology and Medical Oncology at The University of Texas Health Science Center San Antonio and is the leader of the gastrointestinal malignancies and geriatric oncology program at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. She received her medical degree from the University of Texas Southwestern Medical School in Dallas, Texas. She completed her internal medicine residency and hematology-oncology fellowship at UT Health San Antonio.
She specializes in medical oncology treatments for gastrointestinal cancers, including gallbladder, bile duct, pancreas, liver and neuroendocrine cancers. Her research interests are drug development for new treatments for hepatobiliary and pancreatic cancers and improving the care for older adults with cancers. She is also a faculty member in Mays Cancer Center's cancer genetics and high-risk screening clinic.
Gender
- Female
Languages Spoken
- English
- Spanish
- Hindi
- Gujarati
-
Credentials
Credentials
Positions
- Associate Professor, University of Texas Health Science Center San Antonio
- Leader, Gastrointestinal Malignancies Program, UT Health San Antonio MD Anderson Cancer Center
- Vice Chief for Clinical Affairs in Hematology and Medical Oncology, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- American Board of Internal Medicine, Hematology
Education
- Medical School: University of Texas Southwestern Medical School, Dallas, Texas
- Residency: Internal Medicine, University of Texas Health Science Center San Antonio, San Antonio, Texas
- Fellowship: Hematology/Oncology, University of Texas Health Science Center San Antonio, San Antonio, Texas
-
Locations & Contact
Locations & Contact
She is very compassionate and really listened to my concerns.
Patient
-
Research & Publications
Research & Publications
View All Publications, Sukeshi Patel Arora, MD
-
Clinical Trials
Clinical Trials
Type of Cancer
Colon
ClinicalTrials.gov Identifier
NCT02891538
Principal Investigator
Sukeshi Patel Arora, MD
A Pilot Study to Evaluate the Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal cancer (CRC) Patients with Curative Resections
This will be a randomized, controlled pilot trial of patients with histological documentation of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer. If patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, then the patient is eligible. All eligible subjects will be consented prior to surgery.
Type of Cancer
Liver
ClinicalTrials.gov Identifier
NCT03037437
Principal Investigator
Sukeshi Patel Arora, MD
Modulation of Sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora, MD
Biomarker development for predicting immune checkpoint therapy efficacy of hepatocellular carcinoma (CTMS# 22-0050)
We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study.
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora, MD
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
This will be a long-term multi-center study to comprehensively study patients with primary liver cancer (PLC).
Type of Cancer
Colorectal Cancer
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora, MD
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Me
This is a Phase 1b/2, randomized, multicenter, open-label study to investigate the efficacy and safety of LBL007 plus tislelizumab in combination with bevacizumab plus capecitabine, or LBL-007 in combination with bevacizumab plus capecitabine versus bevacizumab plus capecitabine, in PD-L1 positive and negative population respectively (Arm A versus Arm C in PD-L1 positive population group, and Arm…
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora, MD
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that
START-001 is a two-part, open label, FIH Phase 1/2 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of STAR0602 as a monotherapy in subjects with advanced solid tumors.
Type of Cancer
Carcinoma
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora, MD
Phase II Single Arm Study of Tremelimumab and Durvalumab (MEDI 4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B)
This is a single-arm, phase II study of patients with advanced HCC with Child-Pugh B cirrhosis who are eligible for first-line treatment with T300+D.